MAP2K1

Across TCGA pan-cancer cohorts, MAP2K1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAP2K1 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MAP2K1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAP2K1 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where MAP2K1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.409	0.941	.010	4	view →
CCRCC	OS	Median	All	0.768	0.908	.034	3	view →
PDAC	DFS	Median	III,IV	0.492	0.833	.041	1	view →
LSCC	DFS	Median	All	1.000	0.905	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MAP2K1–LUAD (DFS)

Open the LUAD breakdown →